JPMorgan Chase & Co. Buys 69,167 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

JPMorgan Chase & Co. boosted its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 220.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,517 shares of the company's stock after buying an additional 69,167 shares during the period. JPMorgan Chase & Co. owned about 0.13% of Trevi Therapeutics worth $336,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TRVI. BNP Paribas Financial Markets grew its holdings in shares of Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock worth $40,000 after purchasing an additional 6,764 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Trevi Therapeutics during the third quarter worth approximately $63,000. Hsbc Holdings PLC bought a new stake in shares of Trevi Therapeutics during the second quarter valued at approximately $61,000. SG Americas Securities LLC bought a new position in Trevi Therapeutics in the 3rd quarter worth approximately $78,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock worth $73,000 after buying an additional 11,450 shares in the last quarter. Institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Trading Up 1.0 %

TRVI stock opened at $3.90 on Friday. The firm has a market cap of $299.78 million, a PE ratio of -8.86 and a beta of 0.87. The stock has a 50-day moving average price of $3.65 and a 200-day moving average price of $3.24. Trevi Therapeutics, Inc. has a 1-year low of $1.35 and a 1-year high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). During the same quarter in the prior year, the business posted ($0.08) EPS. On average, analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. D. Boral Capital reissued a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, January 8th. B. Riley reissued a "buy" rating and set a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. HC Wainwright increased their price target on Trevi Therapeutics from $6.00 to $7.50 and gave the company a "buy" rating in a research note on Thursday, December 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Trevi Therapeutics currently has an average rating of "Buy" and a consensus target price of $9.31.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.